Physician profile
Sumit K Gupta
NPI 1487662003
$5,084.42
in general payments reported to CMS, 2019-2025
20 companies · $910 in 2025
The $910 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $448 · 2020: $40.77 · 2021: $517 · 2022: $1,408 · 2023: $1,222 · 2024: $540 · 2025: $910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,670.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,327.25 | 2019-2025 | Clareon, Lensx, Clareon Panoptix Pro |
| Abbvie INC. | $302.01 | 2022-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $253.74 | 2023-2025 | Tecnis Simplicity |
| New World Medical,INC. | $223.82 | 2023-2024 | Clearpath, Kahook Dual Blade, Ahmed Glaucoma Valve |
| Oyster Point Pharma, INC. | $134.08 | 2022-2023 | Tyrvaya |
| Bausch & Lomb Americas INC. | $129.55 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Biotissue Holdings INC. | $117.42 | 2021-2022 | |
| Heru, INC. | $112.73 | 2022 | |
| Novartis Pharmaceuticals Corporation | $89.54 | 2022 | |
| Horizon Therapeutics Plc | $64.78 | 2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $63.71 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $54.72 | 2019-2021 | |
| Allergan, INC. | $43.22 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $41.36 | 2019 | |
| Ocular Therapeutix, INC. | $40.02 | 2023 | Dextenza |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $22.38 | 2024 | Tepezza |
| Rayner Intraocular Lenses Limited | $19.76 | 2023 | Rayone Emv, Rayone Spheric, Omidria |
| Eyepoint US, INC. | $16.40 | 2019 | |
| Optinose US, INC. | $15.53 | 2019 | |
| Kala Pharmaceuticals, INC. | $12.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumit Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.